Tesis Biosciences Partners with Frontier Management to Provide Exclusive Pharmacogenetic Testing for Residents of Frontier’s Senior Living Facilities

PHOENIX and PORTLAND, Ore., March 16, 2022 – Tesis Biosciences, the leader in targeted genetic sequencing, and Frontier Management, one of the largest senior housing providers in the U.S., have announced an agreement under which Tesis will be the exclusive provider of pharmacogenetic testing for residents of the company’s communities.

Frontier operates more than 130 independent living, assisted living and memory care facilities across 21 states. As part of its package of services to residents, Frontier provides basic healthcare. Under this agreement, Tesis will conduct all pharmacogenetic testing for Frontier facility residents and serve as the testing arm of Frontier’s pharmaceutical management program for residents.”

“The main premise behind this program is to not only more accurately synchronize patients with the proper medications, but also to look at their genetic predisposition for metabolizing certain drugs should they need more advanced treatment such as for cancers or neurogenic type conditions,” said Tesis CEO Ron King. “This is critical because 85% of this population has two or more chronic conditions and are already on multiple medications.”

Chronic conditions such as heart disease, cancer, diabetes, lung disease and Alzheimer’s are among the leading causes of death in the U.S. and consume up to 90% of the nation’s annual healthcare costs. Tesis uses a genetically integrated medical platform for targeted genetic sequencing and comprehensive genetic data collection to fuel breakthroughs in chronic disease management.

With its genetically integrated medical platform for targeted genetic sequencing, comprehensive genetic data collection and ability to create proprietary, narrowly focused diagnostics panels, Tesis will help drive better drug efficacy, utilization, diagnostics and therapeutics for the Frontier population.

The Tesis program also will include a study to determine how effective pharmacogenomic testing can be in helping to prevent falls, which are common among senior populations and often are connected to mismanagement of medications. Falls among adults ages 65 and older each year cost about $50 billion in medical expenses related to non-fatal fall injuries, while

$754 million is spent related to fatal falls, according to the Centers for Disease Control and Prevention.